260 related articles for article (PubMed ID: 25468228)
1. Current medical treatment of glioblastoma.
Venur VA; Peereboom DM; Ahluwalia MS
Cancer Treat Res; 2015; 163():103-15. PubMed ID: 25468228
[TBL] [Abstract][Full Text] [Related]
2. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options in recurrent glioblastoma--An update.
Seystahl K; Wick W; Weller M
Crit Rev Oncol Hematol; 2016 Mar; 99():389-408. PubMed ID: 26830009
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Nagaiah G; Almubarak M; Khan M; Altaha R
Cancer Invest; 2010 Dec; 28(10):1048-53. PubMed ID: 20873990
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for the treatment of glioblastoma.
Chowdhary S; Chamberlain M
Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
Clarke JL
Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
[TBL] [Abstract][Full Text] [Related]
8. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC
Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
[TBL] [Abstract][Full Text] [Related]
9. The role of Gliadel wafers in the treatment of high-grade gliomas.
Bregy A; Shah AH; Diaz MV; Pierce HE; Ames PL; Diaz D; Komotar RJ
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1453-61. PubMed ID: 24236823
[TBL] [Abstract][Full Text] [Related]
10. Current therapeutic options for glioblastoma and future perspectives.
Aquilanti E; Wen PY
Expert Opin Pharmacother; 2022 Oct; 23(14):1629-1640. PubMed ID: 36100970
[TBL] [Abstract][Full Text] [Related]
11. How did lomustine become standard of care in recurrent glioblastoma?
Weller M; Le Rhun E
Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
13. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
15. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
16. [Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Imai R; Sasaki H
Brain Nerve; 2022 May; 74(5):677-684. PubMed ID: 35589663
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
18. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
Qin D; Mo H; Ou G
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):168-9. PubMed ID: 11783028
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
